By Dan Stanton+ 03-Feb-2015
Novo Nordisk will invest up to $760m in its manufacturing network in the coming year to support the growth of its insulin portfolio.
Patented, Single-Pass TFF Revolutionizes Bioprocessing
For 2015, capital expenditure at the Denmark-based biopharma firm is expected to be around DKK 5bn ($760m), CEO Jesper Brandgaard said in a conference call to discuss end-of-year results Friday.
This will be “primarily related to investments in the expansion of manufacturing capacity for biopharmaceutical products, expansion of insulin filling capacity, additional capacity for insulin API production as well as construction of new research facilities,” he told investors.
Company spokesman Mike Rulis told Biopharma-Reporter.com his CEO’s comments reflected a gradual expansion of the firm’s network to support the manufacture of its diabetes products, which includes Victoza – a GLP-1 therapy for type 2 diabetes – and long acting basal insulin Tresiba.
“We completed a large [insulin-producing] plant in China which went online about three years ago and we have seen frequent expansions there, as well as sites in the US, France, Brazil and Denmark,” he said, adding these “strategic plants” are able to supply multiple products to multiple countries. Over $100m was invested in an insulin purification plant in Denmark last year.
Furthermore, last August the company acquired a facility in West Lebanon, New Hampshire, from Olympus Biotech and some of the $760m will be used to refit the site to commercially manufacture Novo Nordisk’s haemophilia treatment pipeline. The site is expected to begin operations later this year.
In-house production
Novo Nordisk is unique among the Big Pharma companies in the fact it manufactures nearly all of its products in-house.
“Some components for device systems are outsourced,” Rulis told us, “and the API for one of our smaller products is in-licensed [Prandin, a tablet for type 2 diabetes, made by Boehringer Ingelheim],” but everything else is made by Novo Nordisk.
“It serves us well as we can apply and control our same systems such as IT and quality globally,” he continued, and, when asked about the problem of over-capacity experienced by a number of other Big Biopharma firms, said the strategy of gradual expansion has meant it has never been in such a situation.
For the full year, sales stood at DKK 89bn ($14bn), up 6% year-on-year, comprising of DKK 42bn worth of sales of modern insulin products (up 9%) and DKK 13bn for Victoza (up 15%).
Related NewsNovo Nordisk to launch IT wing as separate company
Novo Nordisk to launch IT wing as separate company
Kalundborg, Denmark, where Novo Nordisk is building a new haemostasis plant
Novo Nordisk building $225 Danish plant to support haemophilia drugs
Novo opts to build US API capacity for semaglutide rather than outsource
To supply the Dane: Novo expects First API batch in 2020
Pictorial representation of Marco Polo's journey from 1375
China's Ausia BioTech seeks international pharma customers
Hillerød lies 40 minutes north of Copenhagen, Denmark
Novo Nordisk $175m diabetes plant to create 450 jobs
Photo - designer491/iStock
Novo Nordisk targets type 2 diabetes mAbs in Xoma licensing deal
Production facilities at Novo Nordisk's Kalundborg plant
Novo Nordisk subpoenaed over Danish manufacturing site
Novo Nordisk $69m Plant Conversion For New Diabetes Drug
Novo Nordisk $69m Plant Conversion For New Diabetes Drug
Novo Nordisk HQ
400 R&D jobs cut as Novo Nordisk says goodbye to inflammatory work
Novo Nordisk: 90 Years of Insulin and Still "Room for Improvement"
Novo Nordisk: 90 Years of Insulin and Still "Room for Improvement"
Novo Nordisk snaps up Olympus plant and rehires laid off NH workers
Novo Nordisk snaps up Olympus plant and rehires laid off NH workers
Denmark's Novo Nordisk licenses yeast-based mAb tech
Novo Nordisk takes Adimab's mAb tech in-house
Novo has turned around the biomanufacturing facility quickly
Novo Nordisk to hire 90 at newly acquired plant in New Hampshire
Novo Nordisk invests $100m in diabetes pipeline purification plant
Novo Nordisk invests $100m in diabetes pipeline purification plant
'Novo Nordisk US HQ BD' 카테고리의 다른 글
| Intercontinental (0) | 2016.04.24 |
|---|---|
| CalSTRS,aum $186.8 billion as of March 31, 2016. CalPERS(The California Public Employees' Retirement System) with $300.3 billion (0) | 2016.04.24 |
| Goldman Sachs raised Novo Nordisk A/S from a “buy” rating to a “conviction-buy” (0) | 2016.04.23 |
| New Jersey Key Industry Clusters. (0) | 2016.04.19 |
| Top 5 Industries in New Jersey.1.Biopharmaceuticals . (0) | 2016.04.19 |